trending Market Intelligence /marketintelligence/en/news-insights/trending/aqibtrx2udi-ohcnkgdoog2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eisai's epilepsy drug Fycompa accepted for review in China

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Eisai's epilepsy drug Fycompa accepted for review in China

Japan's Eisai Co. Ltd. said the new drug application for its epilepsy drug Fycompa has been accepted for review in China.

The National Drug Administration of China will review Fycompa as an adjunctive treatment for partial onset seizures in epilepsy patients 12 and up. Adjunctive treatments are to be used with a primary therapy.

The application is supported by data from three late-stage trials conducted mainly in Europe and in the U.S., as well as data from a late-stage trial conducted mainly in Asia.

Epilepsy is categorized by seizure type, with partial onset seizures accounting for about 60% of epilepsy cases and generalized seizures for 40%. In a partial-onset seizure, an abnormal disturbance occurs in a limited area of the brain and may spread to become a generalized seizure. In a generalized seizure, disturbances occur throughout the brain and can be followed by a loss of consciousness.

In China, about 9 million people have epilepsy with about 60% impacted by partial onset seizures. Of those being impacted by partial onset seizures, about 40% need adjunctive treatment.

Fycompa, also known as perampanel, is approved in over 55 countries as an adjunctive treatment for partial onset seizures. The drug is also approved to help treat primary generalized seizures in over 50 countries. In the U.S., Fycompa can be used as a standalone or as an adjunctive treatment for partial onset seizures.